input appreciated .. but as i've always explained
i do
input appreciated .. but as i've always explained
i do this documentation for my own edification
if others can benefit from seeing *liquidity* done
daily .. or NITE or CDEL or PAUL *blocking* on
the ask via l2 re: trades .. or what % of hidden trades go off ..
that is great .. but my posts are specifically done for me
welcome to the IPIX SMB on ihang and your first post ..
i have had a feeling i'd be seeing some new aliases here after
noting what NR (non retail for new eyes) *reported*
recently re: IPIX .. and good catch on noting the *overlap*
of IPIX and another OTC target .. crews' focus on that other one too
both targets retain actual investors ..
both targets have enviable share structures a decade later .. allowing for *options*
both targets have been relentlessly compressed PPS wise (cycles of $/handoff)
both targets have *imo* aware mgmt teams .. which matters to *me*
and targets have overlapping *crews* .. embedded for years now
some of whom truly could go for the gold medal re: minutiae & FUD
to my knowledge .. if *anyone* asks me to expand on what i'm saying .. i do so
unless of course i have that *alias* on ignore
gl with your stock investments ..
4kids
====================
4kids,
I have been a biotech investor for many years and I have regularly watched posts here and there. I rather find your posts informative and I have done some of my own digging to see this is a trend in the over the counter world. Thank you for your posts although I do wish they were more understandable.
What format do you use to write your posts? The common investor could use this information but I feel the common investor as myself may just glance through your posts because they are too hard to understand specifically due to your writing format. Maybe you can use more standardized English grammar to really educate the people here. Seems like you write the posts elsewhere then copy and paste which may make the posts discombobulated a bit besides the constant acronyms and **accents**.
We appreciate your hard work and diligence to this stock and others I have seen you post on.
8
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
transcosmos Dominates CCAM Awards Night Sometimes, it's like flipping a coin and watching it land heads thrice—consistency, skill, a touch of guts. That's transcosmos at the CCAM Industry Excellence Awards 2026 in Malaysia, snagging a gold, a silver, and a bronze in one swoop. They didn't just show up; they delivered a masterclass in customer service excellence, people...
Continue Reading
Hit the Deck: Qfin's Legal Storm Brews When the suits begin to rumble, it’s high time to pull up a seat and watch how these chips fall. If you're parking your funds under NASDAQ:QFIN—heads up! A shareholder rights firm is bringing a class-action lawsuit, and investors perched between March 18 and August 25, 2026, should be ready to jump ship or fight. The Mighty...
Continue Reading
Bybit Plays the Game of Expansion Step right up to Bybit’s latest offering – ByPick Season 2. Some folks might be scratching their heads about what's shifting in this free-to-play space, but here we are, watching a beast that’s a mix between a carnival game and a hedge fund playpen. No money exchanged, just knowledge on the line. That's right, we're diving into a...
Continue Reading
Tony Leung Steals the Spotlight In the theater of Asian cinema, Tony Ka-fai Leung delivers a top-tier performance, earning him the Best Actor award at the Golden Rooster Awards for iQIYI's film "The Shadow's Edge." Now, let's not kid ourselves, snagging one of these prestigious awards is no walk in the park. It's fair to say both this recognition and his first-time win at...
Continue Reading
Trouble at Endava: Leadership Shakeup and Financial Concerns So, here's the kicker—Endava's got itself into one mighty mess worth chewing over with your morning coffee. When your top brass drops like flies, and you're fumbling your financials, investors start sweating bullets. On October 28, 2026, Endava plc (NYSE: DAVA) confesses to some serious accounting missteps....
Continue Reading
Revelations Hit Coastal Financial Hard Alright, pull up a chair and let’s chew over what just happened with Coastal Financial Corporation (NASDAQ: CCB). This is the sort of deal that makes seasoned investors shake their heads in disbelief. Between October 28, 2024, and July 29, 2026, anyone buying into Coastal was buying into a mess they didn’t sign up for. We're...
Continue Reading
Eye on the Aluminum Fluoride Surge Cracking open the numbers, the aluminum fluoride market is projected to swell from $2.48 billion in 2026 to a hefty $3.30 billion by 2031, trucking along at a CAGR of 5.9%. That's no small potatoes in the world of industrial materials. Scratch the surface, and you’ll see what's fueling this climb—think of it as a bellwether for...
Continue Reading
Jensen Huang's Sudden Exit: A Barrage of Headlines In what feels like a blow delivered by a sledgehammer, NVIDIA is rocked by the abrupt resignation of its iconic co-founder and CEO, Jensen Huang. This isn't some quiet departure into the night. Nope, it's more like a cannonball being fired into the investor lounge, leaving a wreckage for all to navigate through. Huang's...
Continue Reading
Signs of Optimism Amidst Financial Struggles Health In Tech is wading through the choppy waters of its Q3 2026 financial results—revenue came in at $6.6 million, down from $8.5 million the previous year. Seems like their investments are all geared up, but the sails aren’t quite catching wind yet. That said, their contracted revenue strutted to $32.7 million for the...
Continue Reading
Healthcare's AI Surge: Jumping the Adoption Hurdle The digital health landscape isn't just humming along—it's hitting high gear. AI, once the shiny toy in innovation's toolkit, is now a fixture in 93.2% of healthcare systems according to CHIME's latest findings. For anyone keeping score, that's a hefty leap and paints a picture where AI isn't just in the game, it's...
Continue Reading
Top 5 Most Recently Viewed Articles
Tesla's Commitment to Community Support During Wildfires Tesla Inc (NASDAQ: TSLA) has recently made headlines for its proactive measures in response to wildfires devastating parts of California. CEO Elon Musk announced that the company's efforts would impact the delivery of Cybertrucks, which are highly anticipated by customers in the affected areas. The decision to delay...
Continue Reading
Aegon's Impressive Performance in the Third Quarter Aegon has recently shared compelling updates about its performance in the third quarter of 2024, showcasing resilience and strategic growth plans despite fluctuating market conditions. The company reported an impressive operating capital generation of EUR 336 million, which reinforces its robust financial position and...
Continue Reading
Earnings Projection for Ribbon Communications Ribbon Communications (NASDAQ:RBBN) is gearing up to unveil its quarterly earnings report soon. Investors are watching closely, seeking signs that the company has not only met but exceeded expectations. According to forecasts, analysts predict an earnings per share (EPS) of approximately $0.05. This announcement is set to stir...
Continue Reading
Investigating Simulations Plus, Inc. for Securities Fraud Recent events have raised significant concerns regarding the financial practices of Simulations Plus, Inc. (NASDAQ: SLP), a prominent software firm specializing in the pharmaceutical and biotechnology sectors. This article explores the unfolding situation, which has financial implications for investors closely...
Continue Reading
NEXE Innovations Reports Strong Growth and Key Milestones NEXE Innovations Inc. (TSXV: NEXE) has recently released its financial results for the quarter that ended in August 2025. The company is making strides in the compostable materials sector and has showcased impressive growth metrics and operational achievements. Financial Highlights for Q1 2026 For the three-month...
Continue Reading